Emily K. Datyner
A5037962349- Autoimmune and Inflammatory Disorders Research
- Rheumatoid Arthritis Research and Therapies
- Inflammatory Myopathies and Dermatomyositis
- Retinal and Optic Conditions
- Cell Adhesion Molecules Research
- Systemic Lupus Erythematosus Research
- Vasculitis and related conditions
- Adolescent and Pediatric Healthcare
- Eosinophilic Disorders and Syndromes
- Ocular Diseases and Behçet’s Syndrome
- Virus-based gene therapy research
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Respiratory viral infections research
- Viral gastroenteritis research and epidemiology
Vanderbilt University Medical Center
2020-2025
Monroe Carell Jr. Children's Hospital
2025
Duke University
2024
Abstract Background Depression adversely affects health outcomes in patients with childhood-onset systemic lupus erythematous (cSLE). By identifying depressive symptoms, we can intervene early referrals to mental resources and improve outcomes. The aim of our quality improvement project was increase maintain rates standardized depression screening for youth cSLE seen within pediatric rheumatology clinic. Methods Patients 12 years age or older routine follow-up at clinic from September 16,...
Janus kinase inhibition (JAKi) has been proposed as a treatment for idiopathic inflammatory myopathies to target increased interferon signalling. Predominantly retrospective reports have demonstrated effectiveness of JAKi in refractory juvenile dermatomyositis (JDM). However, remains an off-label JDM and there may be variation use worldwide. An international survey was conducted investigate approaches JDM. The Childhood Arthritis Rheumatology Research Alliance (CARRA) Therapeutics workgroup...
Chronic anterior uveitis (CAU) carries a significant risk for eye complications and vision loss. The Childhood Arthritis Rheumatology Research Alliance (CARRA) introduced consensus treatment plans (CTPs) to standardize CAU facilitate future comparative effectiveness studies. Two CTPs were developed address: 1) initiation of methotrexate (MTX) in patients with naïve steroid-sparing therapy, 2) TNF inhibitor (TNFi) severe or refractory MTX. We evaluated implementation the using existing CARRA...